Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Sell
29
CLB Quote, Financials, Valuation and Earnings
Last price:
$11.09
Seasonality move
:
0.33%
Day range:
$11.15 - $11.82
52-week range:
$10.14 - $25.13
Dividend yield:
0.34%
P/E ratio:
19.86x
P/S ratio:
1.08x
P/B ratio:
2.17x
Volume:
551.4K
Avg. volume:
545.1K
1-year change:
-30.86%
Market cap:
$549.5M
Revenue:
$523.8M
EPS (TTM):
$0.59
Analysts' Opinion
-
Consensus RatingCore Laboratories has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.40, Core Laboratories has an estimated upside of 39.93% from its current price of $11.72.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $11.72.
Fair Value
-
According to the consensus of 3 analysts, Core Laboratories has 39.93% upside to fair value with a price target of $16.40 per share.
CLB vs. S&P 500
-
Over the past 5 trading days, Core Laboratories has underperformed the S&P 500 by -7.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Core Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Core Laboratories revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Core Laboratories reported revenues of $123.6M.
Earnings Growth
-
Core Laboratories earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Core Laboratories reported earnings per share of --.
Enterprise value:
657.7M
EV / Invested capital:
1.71x
Price / LTM sales:
1.08x
EV / EBIT:
12.09x
EV / Revenue:
1.27x
PEG ratio (5yr expected):
0.36x
EV / Free cash flow:
14.96x
Price / Operating cash flow:
12.66x
Enterprise value / EBITDA:
9.50x
Gross Profit (TTM):
$87.6M
Return On Assets:
4.72%
Net Income Margin (TTM):
5.41%
Return On Equity:
11.15%
Return On Invested Capital:
7.17%
Operating Margin:
5.69%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $502.8M | $511.1M | $517.8M | $129.6M | $123.6M | |
| Gross Profit | $87.9M | $92.5M | $87.6M | $21.2M | $20.4M | |
| Operating Income | $46.7M | $57.8M | $46.8M | $9.7M | $7M | |
| EBITDA | $65M | $72.3M | $69.2M | $12.4M | $8.1M | |
| Diluted EPS | $0.50 | $0.78 | $0.59 | $0.07 | -- | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $185.8M | $202.2M | $227.9M | $229M | $228.8M | |
| Total Assets | $584.4M | $584.9M | $593.6M | $588M | $591.5M | |
| Current Liabilities | $85.5M | $99.8M | $95.6M | $85.5M | $103.7M | |
| Total Liabilities | $438.4M | $418.5M | $393.5M | $350.5M | $332.2M | |
| Total Equity | $146M | $166.4M | $200.2M | $237.4M | $259.4M | |
| Total Debt | $208.2M | $189.8M | $180.4M | $160.4M | $124.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $16.5M | $33.5M | $57.5M | $5.5M | $6.7M | |
| Cash From Investing | -$6.3M | -$6.3M | -$4M | -$1.7M | $772K | |
| Cash From Financing | -$15.9M | -$28.6M | -$46.4M | -$4.1M | -$4.5M | |
| Free Cash Flow | $6.4M | $22.1M | $44M | $2.5M | $3.1M | |
CLB
Sector
Market Cap
$549.5M
$60.2M
Price % of 52-Week High
46.64%
57.26%
Dividend Yield
0.34%
0%
Shareholder Yield
2.42%
4.67%
1-Year Price Total Return
-30.86%
-31.04%
Beta (5-Year)
1.994
0.780
Dividend yield:
0.34%
Annualized payout:
$0.04
Payout ratio:
6.7%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$11.99
200-day SMA
Sell
Level
$18.10
Bollinger Bands (100)
Sell
Level
13.66 - 19
Chaikin Money Flow
Buy
Level
1.7M
20-day SMA
Sell
Level
$12.34
Relative Strength Index (RSI14)
Sell
Level
39.74
ADX Line
Sell
Level
38.65
Williams %R
Neutral
Level
-48.4436
50-day SMA
Sell
Level
$14.17
MACD (12, 26)
Buy
Level
0.89
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Sell
Level
-4.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.2951)
Buy
CA Score
(Annual)
Level (-0.1023)
Buy
Beneish M-Score
(Annual)
Level (-2.5557)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (0.6052)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
Stock Forecast FAQ
In the current month, CLB has received 0 Buy ratings 3 Hold ratings, and 0 Sell ratings. The CLB average analyst price target in the past 3 months is $16.40.
-
Where Will Core Laboratories Stock Be In 1 Year?
According to analysts, the consensus estimate is that Core Laboratories share price will rise to $16.40 per share over the next 12 months.
-
What Do Analysts Say About Core Laboratories?
Analysts are divided on their view about Core Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Core Laboratories is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is Core Laboratories's Price Target?
The price target for Core Laboratories over the next 1-year time period is forecast to be $16.40 according to 3 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is CLB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Core Laboratories is a Hold. 3 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CLB?
You can purchase shares of Core Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Core Laboratories shares.
-
What Is The Core Laboratories Share Price Today?
Core Laboratories was last trading at $11.09 per share. This represents the most recent stock quote for Core Laboratories. Yesterday, Core Laboratories closed at $11.72 per share.
-
How To Buy Core Laboratories Stock Online?
In order to purchase Core Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 6.51% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 3% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 5.34% over the past day.
